4//SEC Filing
LEWIS JOEL 4
Accession 0001133416-25-000052
CIK 0001133416other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:01 PM ET
Size
10.1 KB
Accession
0001133416-25-000052
Insider Transaction Report
Form 4
LEWIS JOEL
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2025-11-10$2.39/sh+1,867$4,462→ 834,459 total - Exercise/Conversion
Stock option (right to buy)
2025-11-05−1,867→ 22,363 totalExercise: $2.39From: 2018-12-14Exp: 2027-12-14→ Common Stock (1,867 underlying) - Sale
Common Stock
2025-11-10$6.03/sh−1,867$11,252→ 832,592 total
Holdings
- 2,000(indirect: By Children)
Common Stock
Footnotes (4)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
- [F2]The options vested 100% on December 14, 2018.
- [F3]These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.
- [F4]The shares were sold in multiple transactions at prices ranging from $6.00 to $6.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeother
Related Parties
1- filerCIK 0001725595
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 4:01 PM ET
- Size
- 10.1 KB